Argenx
ARGX
#426
Rank
NZ$94.25 B
Marketcap
NZ$1,513
Share price
-1.30%
Change (1 day)
38.05%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): NZ$15.24

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$15.29. In 2024 the company made an earnings per share (EPS) of NZ$24.00 an increase over its 2023 EPS that were of NZ-$8.90.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$15.24-36.49%
2024NZ$24.00-369.77%
2023NZ-$8.90-60.46%
2022NZ-$22.5063.33%
2021NZ-$13.77-40.37%
2020NZ-$23.10183.47%
2019NZ-$8.15123.09%
2018NZ-$3.6554.93%
2017NZ-$2.3614.07%
2016NZ-$2.0713.05%
2015NZ-$1.83-36.34%
2014NZ-$2.87209.04%
2013NZ-$0.93-33.99%
2012NZ-$1.41185.59%
2011NZ-$0.49